Results 1 to 10 of about 124,717 (304)

Immune checkpoint blockade in HIV

EBioMedicine, 2022
Summary: Antiretroviral therapy (ART) has dramatically improved life expectancy for people with HIV (PWH) and helps to restore immune function but is not curative and must be taken lifelong.
Celine Gubser, Chris Chiu, Sharon R. Lewin, Thomas A. Rasmussen   +3 more
doaj   +5 more sources

Optimization of Immune Checkpoint Blockade via a Multiscale Model System [PDF]

Computational and Systems Oncology
Cancer progresses when cancer cells selectively bind to inhibitory receptors on a T cell surface, downregulating tumor immune response. One standard‐of‐care strategy to combat this process is immune checkpoint blockade.
Anne M. Talkington, Anthony J. Kearsley
doaj   +2 more sources

MCT4 blockade increases the efficacy of immune checkpoint blockade

Journal for ImmunoTherapy of Cancer, 2023
Background & Aims Intratumoral lactate accumulation and acidosis impair T-cell function and antitumor immunity. Interestingly, expression of the lactate transporter monocarboxylate transporter (MCT) 4, but not MCT1, turned out to be prognostic for ...
Christian Schmidl, Wolfgang Herr, Nathalie Babl, Sonja-Maria Decking, Florian Voll, Michael Althammer, Ada Sala-Hojman, Roberta Ferretti, Clarissa Korf, Lisa Schmidleithner, Benedikt Nerb, Carina Matos, Gudrun E Koehl, Peter Siska, Christina Bruss, Fabian Kellermeier, Katja Dettmer, Peter J Oefner, Marvin Wichland, Ines Ugele, Christopher Bohr, Shivapriya Ramaswamy, Timo Heinrich, Christian Herhaus, Marina Kreutz, Kathrin Renner   +25 more
doaj   +4 more sources

Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma

OncoImmunology, 2021
Immune checkpoint therapy has resulted in minimal clinical response in many pediatric cancers. We sought to understand the influence of immune checkpoint inhibition using anti-PD-1 and anti-CTLA-4 antibodies individually, in combination, and after ...
Soheila Shirinbak, Randall Y. Chan, Shilpa Shahani, Sakunthala Muthugounder, Rebekah Kennedy, Long T. Hung, G. Esteban Fernandez, Michael D. Hadjidaniel, Babak Moghimi, Michael A. Sheard, Alan L. Epstein, Muller Fabbri, Hiroyuki Shimada, Shahab Asgharzadeh   +13 more
doaj   +1 more source

Immune checkpoint blockade therapy [PDF]

Journal of Allergy and Clinical Immunology, 2018
Immune checkpoints are accessory molecules that either promote or inhibit T-cell activation. Two inhibitory molecules, cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1), got high attention, as inhibition of CTLA-4 or PD-1 signaling provides the first immune therapy that significantly improves the survival of patients ...
Thomas, Wieder, Thomas, Eigentler, Ellen, Brenner, Martin, Röcken   +3 more
openaire   +2 more sources

A PD-L1 Negative Advanced Gastric Cancer Patient With a Long Response to PD-1 Blockade After Failure of Systematic Treatment: A Case Report

Frontiers in Immunology, 2021
BackgroundIt was widely accepted that programmed death-ligand 1 (PD-L1) positive, tumor mutational burden-high (TMB-H) or microsatellite instability-high (MSI-H) tumor are prone to have better treatment response to immune checkpoint blockade.
Fangyuan Zhang, Jieying Zhang, Lei Zhao, Menglan Zhai, Tao Zhang, Dandan Yu   +5 more
doaj   +1 more source

Metabolic Implications of Immune Checkpoint Proteins in Cancer

Cells, 2022
Expression of immune checkpoint proteins restrict immunosurveillance in the tumor microenvironment; thus, FDA-approved checkpoint inhibitor drugs, specifically PD-1/PD-L1 and CTLA-4 inhibitors, promote a cytotoxic antitumor immune response.
Elizabeth R. Stirling, Steven M. Bronson, Jessica D. Mackert, Katherine L. Cook, Pierre L. Triozzi, David R. Soto-Pantoja   +5 more
doaj   +1 more source

Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma

Nature Communications, 2021
Immune-checkpoint blockade has shown limited benefits in patients with glioblastoma. To understand how the composition of the tumor immune microenvironment might limit clinical responses, here the authors present a high dimensional profiling of the ...
Alexander H. Lee, Lu Sun, Aaron Y. Mochizuki, Jeremy G. Reynoso, Joey Orpilla, Frances Chow, Jenny C. Kienzler, Richard G. Everson, David A. Nathanson, Steven J. Bensinger, Linda M. Liau, Timothy Cloughesy, Willy Hugo, Robert M. Prins   +13 more
doaj   +1 more source

Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy

Nanomaterials, 2021
Immune checkpoint receptor signaling pathways constitute a prominent class of “immune synapse,” a cell-to-cell connection that represses T-lymphocyte effector functions.
Chiara Cremolini, Emanuela Vitale, Raffaella Rastaldo, Claudia Giachino   +3 more
doaj   +1 more source

Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40

Nature Communications, 2021
Glioblastomas are generally resistant to treatment with immune checkpoint inhibitors. Here the authors show that IL6 blockade, in combination with a CD40 agonist, overcomes macrophage-mediated immunosuppression and sensitizes glioblastoma to immune ...
Fan Yang, Zhenqiang He, Hao Duan, Duo Zhang, Juehui Li, Huijuan Yang, Jay F. Dorsey, Wei Zou, S. Ali Nabavizadeh, Stephen J. Bagley, Kalil Abdullah, Steven Brem, Lin Zhang, Xiaowei Xu, Katelyn T. Byrne, Robert H. Vonderheide, Yanqing Gong, Yi Fan   +17 more
doaj   +1 more source